Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/193117
Title: | Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation |
Author: | Schmidt, Hartmut H. Wixner, Jonas Planté Bordeneuve, Violaine Muñoz-Beamud, Francisco Lladó Garriga, Laura Gillmore, Julian D. Mazzeo, Anna Li, Xingyu Arum, Seth Y Jay, Patrick Adams, David Patisiran Post-LT Study Group |
Keywords: | Assaigs clínics Amiloïdosi Biologia molecular Trasplantament hepàtic Clinical trials Amyloidosis Molecular biology Hepatic transplantation |
Issue Date: | Jun-2022 |
Publisher: | Wiley |
Abstract: | Hereditary transthyretin-mediated (hATTR) amyloidosis, or ATTRv amyloidosis, is a progressive disease, for which liver transplantation (LT) has been a long-standing treatment. However, disease progression continues post-LT. This Phase 3b, open-label trial evaluated efficacy and safety of patisiran in patients with ATTRv amyloidosis with polyneuropathy progression post-LT. Primary endpoint was median transthyretin (TTR) reduction from baseline. Twenty-three patients received patisiran for 12 months alongside immunosuppression regimens. Patisiran elicited a rapid, sustained TTR reduction (median reduction [Months 6 and 12 average], 91.0%; 95% CI: 86.1%-92.3%); improved neuropathy, quality of life, and autonomic symptoms from baseline to Month 12 (mean change [SEM], Neuropathy Impairment Score, -3.7 [2.7]; Norfolk Quality of Life-Diabetic Neuropathy questionnaire, -6.5 [4.9]; least-squares mean [SEM], Composite Autonomic Symptom Score-31, -5.0 [2.6]); and stabilized disability (Rasch-built Overall Disability Scale) and nutritional status (modified body mass index). Adverse events were mild or moderate; five patients experienced ≥1 serious adverse event. Most patients had normal liver function tests. One patient experienced transplant rejection consistent with inadequate immunosuppression, remained on patisiran, and completed the study. In conclusion, patisiran reduced serum TTR, was well tolerated, and improved or stabilized key disease impairment measures in patients with ATTRv amyloidosis with polyneuropathy progression post-LT (www.clinicaltrials.gov NCT03862807). |
Note: | Reproducció del document publicat a: https://doi.org/10.1111/ajt.17009 |
It is part of: | American Journal of Transplantation, 2022, vol. 22, num. 6, p. 1646-1657 |
URI: | http://hdl.handle.net/2445/193117 |
Related resource: | https://doi.org/10.1111/ajt.17009 |
ISSN: | 1600-6135 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
725800.pdf | 838.78 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License